Skip to main content
Premium Trial:

Request an Annual Quote

GeneticXchange, InforMax, NetGenics Join GEML Consortium

NEW YORK, Feb 28 – GeneticXchange, Informax, and Netgenics have joined the Gene Expression Markup Language community organized by Rosetta Inpharmatics, Rosetta said Wednesday. 

This community, which Rosetta launched in November 2000, is designed for users and providers who support Rosetta’s GEML file format for gene expression data exchange. The community’s members work together to shape future versions of GEML and encourage it to be applied in genomics. The members make their software GEML compatible.

Rosetta Inpharmatics initially developed the GEML file format to foster collaboration and give researchers a robust, flexible, common language with which to exchange gene expression information," Douglas Bassett, Rosetta’s senior director of biosoftware products and services, said in a statement. "We are pleased that GeneticXchange, InforMax, and NetGenics share our goal to promote discovery through increased ease of data interchange." 

Other GEML members include Agilent Technologies, Europroteome, the Harvard University Center for Genomic Research, Nature Publishing Group, and Spotfire.

Rosetta is distributing GEML for free along with a set of gene expression data visualization tools. For more information on GEML, users can go to  http://www.geml.org .

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.